



Atara Biotherapeutics
Investor Relations Department
701 Gateway Blvd, Suite 200
South San Francisco, CA 94080
United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

NASDAQ: ATRA

Last Trade:	14.00
Trade Time:	1:35 PM ET Aug 17, 2017
Change:	-0.35 ▼ (-2.439%)
Day Range	13.75 - 14.57
52-Week Range	11.80 - 23.40
Volume	115,906


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Atara Biotherapeutics is a leading "Off-the-Shelf" T-cell immunotherapy company developing products for patients with cancer and Multiple Sclerosis (MS). The company was founded in 2012, and since 2014 the company's stock has been publicly traded on Nasdaq under the symbol ATRA.

Atara's most advanced product candidate, ATA129, for cancer patients with rituximab refractory Epstein-Barr virus (EBV) associated Post-Transplant Lymphoproliferative Disease (EBV-... [\(more\)](#))

Stock Performance



Press Releases [\[View all \]](#)

Aug 7, 2017

[Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights](#)

Aug 2, 2017

[Atara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference](#)

Jul 31, 2017

[Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis \(MS\)](#)

May 24, 2017

[Atara Biotherapeutics to Present at Three Upcoming Investor Conferences](#)

Upcoming Events [\[View all \]](#)

Sep 6, 2017

[CAR-TCR Summit 2017](#)

Sep 6-7, 2017 12:00 AM

[Citi Biotech Conference](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 9, 2017

[Annual Report \(10-K\)](#)

Apr 25, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 7, 2017

[Quarterly Report \(10-Q\)](#)

May 4, 2017

[Quarterly Report \(10-Q\)](#)

Nov 4, 2016

[Quarterly Report \(10-Q\)](#)